Transcode Therapeutics, Inc.

TransCode is a clinical-stage biotechnology company that develops immuno-oncology and RNA-targeted therapeutics for the treatment of high-risk, advanced, and metastatic cancers. The company utilizes its proprietary TTX modular drug design engine to create delivery vehicles for synthetic oligonucleotides targeting genetic elements outside the liver. Its product candidates include TTX-MC138, an antisense inhibitor targeting microRNA-10b for solid tumors, alongside preclinical programs TTX-siPDL1, TTX-RIGA, and TTX-siMYC. Through acquisitions and licensing, TransCode also develops Seviprotimut-L, a polyvalent vaccine for stage IIB and IIC melanoma, and an oncolytic adenovirus immunotherapy platform directed at solid tumors including muscle-invasive bladder cancer. Its pipeline serves cancer patients with high unmet medical needs.

The company conducts clinical and preclinical stage development, carrying out multicenter clinical trials in collaboration with research organizations such as the MD Anderson Cancer Center. It acquired subsidiary operations including Polynoma, LLC, which is located in San Diego, California. The text does not state the company's founding year, website, or overall corporate headquarters.

Summary of the business section of Transcode Therapeutics's latest annual report, written by StockData.

“As of April 3, 2026, we had 12 employees, all of whom are full-time.”